Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Inst
CPTR Newsletter – December 2018 CPTR Newsletter – December 2018 In this issue: In the Spotlight: TB-ReFLECT Manuscript Published Updates to the TB
December 13, 2019 Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials
U.S. Food and Drug Administration Awards Contract to Critical Path Institute for Kidney Transplant Database Patient-level data will inform the creation of drug development tools and speed development of new immunosuppressive treatments TU
December 1, 2018 Brief Overview: Assessment of Compound-induced Acute Kidney Injury Using Animal Models, Biomarkers, and In Vitro Platforms
Sharing Data to Accelerate Medicines Development and Improve Neonatal Care: Data Standards and Harmonized Definitions
October 11, 2018 Comparability of a Provisioned Device Versus Bring Your Own Device for Completion of Patient-Reported Outcome (PRO) Measures by Participants with Chronic Obstructive Pulmonary Disease (COPD): Quantitative Interview Findings
Profiles in Business with Tucson Metro Chamber C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact a
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme
November 3, 2018 D-RSC and PSTC presented “Biomarkers for Muscle Diseases” poster at the 2018 MDA Clinical Conference